

Anti-B7-H4 [#36-1] Standard Size Ab02670-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric human antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: #36-1

Alternative Name(s) of Target: B7H4; B7 homolog 4; B7h.5; O8E; Immune costimulatory protein B7-H4; B7S1; Protein B7S1; B7x; T-cell costimulatory molecule B7x; VTCN1

UniProt Accession Number of Target Protein: Q7Z7D3

Published Application(s): ELISA, FC

Published Species Reactivity: Human

Immunogen: The original antibody was generated by immunizing BALB/c mice with recombinant human B7-H4 as immunogen.

Specificity: This antibody binds human B7-H4, which inhibits T cell proliferation and causes secretion of IL-2. It is overexpressed in breast, ovarian, endometrial, renal cell (RCC) and non-small-cell lung cancers (NSCLC).

Application Notes: The binding specificity of this antibody towards B7-H4 was determined using ELISA. This antibody was used to screen B7-H4 positive human breast adenocarcinoma cell lines SKBR-3 using flow cytometry (US20180118831; Epstein Alan, 2013- B7-H4 as a Target for Breast Cancer Immunotherapy)

Antibody First Published in: Epstein et al. Car t-cells for the treatment of b7-h4 expressing solid tumors. US20180118831 [PMID:](#)

Note on publication:

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.